An analysis of the serologic data (S2 and S3 Tables) showed that 32% of all CLL patients failed to seroconvert or develop D614G NAbs following vaccination (S-NAb-), while 42% developed both anti-S binding Abs and NAbs (S+NAb+). This evidence concerns the gene DDX41 and B-cell chronic lymphocytic leukemia.